About WWHS

WWHS Biotech Inc. ("WWHS") is a holding subsidiary of Sansure Biotech Inc. (stock code: 688289), co-founded by Professor Hongjie Dai, a world-renowned chemist, member of the U.S. National Academy of Sciences, the U.S. National Academy of Medicine, and the American Academy of Arts and Sciences, and a Foreign Member of the Chinese Academy of Sciences. Built on second near-infrared window (NIR-II) fluorescence enhancement technology, the company is a National High-tech Enterprise and among the first to bring NIR-II fluorescence technology to in vitro diagnostics (IVD).

WWHS has developed nearly 100 NIR-II fluorescence point-of-care testing (POCT) products spanning inflammatory and infection markers, cardiac markers, tumor markers, and diabetes management. With superior anti-interference, ultra-high sensitivity, and outstanding stability, its platform breaks through the limitations of conventional POCT. Certified under NMPA and CE, WWHS serves numerous countries and regions worldwide, working to make NIR-II precision testing accessible to all.

Patent Applications
40+
Patent Applications Covering materials, manufacturing, and testing
Test Items
100+
Test Items Covering diverse clinical testing needs
Registrations & Certifications
20+/60+
NMPA / CE Certifications 20+ NMPA Registrations · 60+ CE Certifications
Authoritative Qualifications
3
Authoritative Qualifications National High-Tech · Specialized & Innovative · ISO13485

Global Presence

Serving 20+ Countries and Regions Worldwide

China

Guangdong · Shandong · Sichuan · Hubei · Jiangsu · Zhejiang · Hainan · Tibet · Henan · Hunan

Asia

Mongolia · Indonesia · Vietnam · Malaysia · Philippines · Syria · Iraq · Israel

Europe

France

Africa

Egypt · Nigeria · Cameroon · Tanzania · Senegal · Burkina Faso · Togo · Benin · Uganda · Kenya

Americas

Guatemala

Oceania

Fiji

Data updated as of: September 3, 2026

Cookie Notice

We use cookies to optimize your browsing experience. Click "Accept" to agree to our use of cookies.